ReviewGalen medical journal2025
Research Progress of A20 in Acute Leukemia: A20 in Acute Leukemia.
Review in Galen medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute leukemia (AL) is a malignant tumor originating from hematopoietic stem cells. Its outstanding feature is the abnormal proliferation and aggregation of clonal leukemia cells in bone marrow and other hematopoietic tissues. Although chemotherapy, targeted immunotherapy and hematopoietic stem cell transplantation have been widely used in clinic, there are still relapse and refractory cases in AL patients. Finding new therapeutic targets and screening prognostic molecules are of great significance for the treatment and prognosis of AL. A20 protein, also known as tumor necrosis factor α-induced protein 3 (TNFAIP3), is a key protein that negatively inhibits the activation of nuclear transcription factor kB (NF-κB) and plays an important role in anti-tumor immune and inflammatory response. In leukemia and lymphoma, A20 is often inactivated, mutated or deleted. Lack of A20 can significantly inhibit the surveillance function of immune cells and mediate tumor immune escape. Therefore, exploring the mechanism of A20 in AL may have important research value and clinical significance for the treatment of AL. The purpose of this paper is to review the research progress of A20 in acute leukemia, and provide new theoretical basis and reference value for the pathogenesis research and targeted therapy of leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.